Celgene Hat Trick: Pomalyst Joins Multiple Myeloma Arsenal
In October 2012, the FDA cancelled the Oncologic Drugs Advisory Committee meeting scheduled for Nov. 8, which was to include a review of the new drug application for pomalidomide, Celgene Corp.'s immunomodulatory drug (IMiD) candidate in multiple myeloma (MM).
Notification came in the aftermath of Hurricane Sandy, which played havoc not only with lives and property up and down the East Coast, but also with business and government schedules, including adcom meetings.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST